Pacira | PCRX - Sales Revenues


Pacira reported $192.4M in Sales Revenues for its fiscal quarter ending in June of 2026.





Sales Change Date
Astellas Pharma JPY 640.91B 102.98B Jun/2026
Bristol-Myers Squibb USD 13.07B 100M Sep/2026
Cara Therapeutics USD 2.57M 1.11M Mar/2025
Coherus Biosciences USD 12.75M 1.18M Dec/2025
Heron Therapeutics USD 40.59M 2.38M Dec/2025
Ironwood Pharmaceuticals USD 113.04M 6.53M Jun/2026
J&J USD 25.4B 89M Sep/2026
Ligand Pharmaceuticals USD 78.75M 4.95M Sep/2026
Nektar Therapeutics USD 10.86M 10.95M Mar/2026
Novo Nordisk DKK 78.49B 18.33B Jun/2026
Pacira USD 192.4M 15.4M Jun/2026
Perrigo USD 1.02B 51M Jun/2026
Pfizer USD 15.03B 530M Jun/2026
Supernus Pharmaceuticals USD 226.8M 7.7M Sep/2026
Teva Pharmaceutical Industries USD 12.67B 900M Jun/2026
Xeris Pharmaceuticals USD 83.13M 2.68M Mar/2026
Zoetis USD 2.5B 200M Jun/2026